As a result of the 25-year research phase, Anodynal® was developed, which is a breakthrough peptide non-narcotic painkiller.
The project addresses the shortage of relatively inexpensive, safe and effective non-narcotic pain medications for patients suffering from moderate to moderately severe pain, both nociceptive and neuropathic, including in various malignant tumors, especially metastatic bone tumors and at terminal stages diseases.
A new type of anesthetic compounds has been developed, low molecular weight peptides with a non-narcotic type of anesthesia, which are synthetic analogs of the minimum fragment of salmon calcitonin molecule that retains the analgesic activity of the full-length molecule.
Selected and patented in Russia (RU 2.508.295), USA (US 9.260.482), Canada (CA 2.867.994), Japan (JP 6.118.392), EU (EU 2.848.629) and Indonesia (ID P000053884) 288 variants of peptide sequences differing most stability and effectiveness of analgesic action.
The mechanism of action of a new type of anesthetic compounds has been investigated and patented (Patent RU 2.651.491 "Specific peptide inhibitors of clathrin"), which consists in suppressing clathrin-mediated endocytosis and reducing the availability of synaptic vesicles, resulting in a reduction in synaptic pain signal transmission: https://journals.sagepub.com/doi/full/10.1177.
In preclinical studies, a high specific activity of Anodynal® has been shown, which is superior in strength to the analgesic effect of the reference drug, ketorolac tromethamine (comparable to morphine, far superior to other NSAIDs): https://pharmvestnik.ru/content/news.
Since 2014, SRC "BIOPHARMOS" is a participant in the Skolkovo Innovation Center creation project.